Profit Or Loss [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Profit (loss) from operating activities
43 735 EUR
22 986 EUR
Finance income
1 695 EUR
2 177 EUR
Finance costs
5 598 EUR
2 412 EUR
Profit (loss) before tax
39 832 EUR
23 221 EUR
Tax expense (income)
2 387 EUR
219,000 EUR
Profit (loss)
37 445 EUR
37 445 EUR
23 003 EUR
23 003 EUR
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share
171.00
118.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share
146.00
118.00

Talk to a Data Expert

Have a question? We'll get back to you promptly.